SUMMARY A double-blind crossover study of sodium valproate and placebo was conducted in five patients with Meige syndrome. CSF neurotransmitter studies were performed at the end of each treatment period. GABA levels were not influenced by the administration of sodium valproate. An increase in HVA levels was observed in every patient, which may reflect an increase in central dopaminergic activity. This finding may explain the trend towards clinical deterioration which was observed during treatment with sodium valproate. Sodium valproate appears to be ineffective in Meige syndrome.
Most pharmacological studies dealing with Meige syndrome (idiopathic or essential blepharospasm and oromandibular dystonia) have been based on the assumption of disruption of reciprocal dopaminergicacetylcholinergic influences in the basal ganglia.`3 Treatment based on this assumption has yielded inconsistent results. 4 Decreased CSF gamma-aminobutyric acid (GABA) levels in adult onset dystonia have been reported,5 suggesting central GABA deficiency in this group of disorders. Several uncontrolled studies employing GABA mimetic or facilitating agents in Meige syndrome with a favourable effect have been reported.6`9 Sodium valproate is a GABA mimetic agent10 and an increase in CSF GABA levels in humans during administration of sodium valproate in therapeutic doses has been reported. " 12 We conducted a double-blind crossover study in five patients with Meige syndrome, in order to test the following hypothesis: sodium valproate has a beneficial effect in Meige syndrome by restoring decreased central GABA activity, which is demonstrable by an increase in CSF GABA levels during treatment.
Methods
Five patients with Meige syndrome gave informed consent for the trial. Individual characteristics are shown in the table. In accordance with Meige's original description,"3 only patients with both blepharospasm and oromandibular dystonia were included; in all patients blepharospasm, interfering with normal vision, was the major symptom. Treatment periods with sodium valproate and placebo lasted 6 weeks and the sequence in which the drugs were administered was randomised. All other medication known to exert an influence on the central nervous system was stopped at least 2 weeks prior to the study. Sodium valproate was given three times daily in increasing doses up to 20 mg/kg at the end of the first week; an identical scheme was used for the placebo tablets. After 6 weeks the medication was discontinued and after a drug free interval of 2 weeks duration the next phase started with the same build up of medication. The patients were seen at 2-week intervals for evaluation and for medication adjustment by an independent clinician. Lumbar puncture was performed under standard conditions at the end of both treatment phases; on the same day, sodium valproate serum levels were monitored at 8 hour intervals.
Patients were admitted at least 24 hours prior to the lumbar punctures and started on a vanillyl mandelic acid (VMA) restricted diet. After a fasting and bedrest period of 12 hours lumbar puncture was carried out between 8 and lOam with the patient in sitting position. CSF was acidified with 1 drop formic acid per ml and frozen at -80°in small portions. The concentrations of 3-methoxy-4-hydroxyphenylglycol (MPHG), homovanillic acid (HVA), 5-hydroxy-indoleacetic acid (5-HIAA) and GABA were determined by high performance liquid chromatography (HPLC). MHPG, Meige syndrome: double-blind crossover studi of sodium valproate (4) blind rating of randomised video tapes. All patients rated the severity of their symptoms everyday on a scale of 0 to 10; only the scores of the 2-weekly examination dates were taken into account. Dystonic movements were assessed by the senior author separately in upper and lower face and rated for severity: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. Surface EMG recordings and videotapes were made on each examination with the patients in standardised postures (that is, at rest, reading aloud and attempting to suppress the abnormal movements, for I minute each). All EMG recordings were made using surface electrodes placed on frontal, orbicularis oculi, orbicularis oris and platysma muscles. Recordings were randomised and rated by a neurophysiologist blinded to the names of the patients and the medications administered. Likewise, the randomised videotapes were independently scored by two raters.
For each evaluation variable, scores were ranked from best to most severe (6-1) for each patient. The summed ranks within the placebo and sodium valproate groups were then compared.
Results
Treatment with sodium valproate at therapeutic serum levels (mean: 79-3 pg/ml, range: 44-128 Mg/ml) did not result in clinical improvement (fig 1) . In fact, in all comparisons sodium valproate was slightly inferior to placebo. Mean CSF GABA levels were not decreased below reference values in the placebo phase and no increase was observed during treatment with sodium valproate (fig 2a) . However, CSF HVA levels increased in all patients during treatment with sodium valproate (p = 0 03 on the assumption of no effect on HVA level) (fig 2b) . No significant effect was observed on both MHPG and 5-HIAA levels, but mean baseline (placebo) MHPG levels were elevated above reference control values (fig 2c) .
Discussion
The 
